Spontaneous Coronary Artery DissectionNorDen-SCAD ExNCT07785765
Norwegian Danish Spontaneous Coronary Artery Dissection Exercise Study
A study testing High intensity interval training (HIIT) in people with Spontaneous Coronary Artery Dissection and Myocardial Infarction (MI), run by Oslo University Hospital at 1 site in Norway.
Trial summary
The goal of this randomized clinical trial is to determine whether a supervised high-intensity interval training (HIIT) program can safely improve cardiorespiratory fitness and overall health in adults who have previously had spontaneous coronary artery dissection (SCAD), a non-atherosclerotic cause of heart attack… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Spontaneous Coronary Artery Dissection, Myocardial Infarction (MI), High Intensity Interval Training
- What is being tested?
- High intensity interval training (HIIT)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteNorway
- Study dates
- 1 Jan 2027to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Confirmed SCAD, at least 12 weeks since last event, age 18 years or older, medically stable and cleared for CPET and supervised exercise
Who cannot join
- Disease with exercise restrictions, exercise related severe hypertension on CPET (>220 mmHg in Systolic blood pressure or >110mmHg in Diastolic blood pressure)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Norway1 site
Rikshospitalet, Department of Cardiology, ProCardio Center for Innovation
Oslo, 0372
About this study
The goal of this randomized clinical trial is to determine whether a supervised high-intensity interval training (HIIT) program can safely improve cardiorespiratory fitness and overall health in adults who have previously had spontaneous coronary artery dissection (SCAD), a non-atherosclerotic cause of heart attack that often affects younger women.
Participants are women and men aged 18 years or older, with a confirmed SCAD at least 12 weeks before enrollment, who are medically stable, cleared for exercise testing, and able to attend supervised sessions.
Read more
The main questions the study aims to answer are:
- Does a 12-week supervised HIIT program lead to a greater improvement in cardiorespiratory fitness (measured as peak oxygen uptake (VO2peak, ml/kg/min)) compared with usual care, without increasing the occurrence of major adverse cardiovascular events (MACE)?
- Is a 12-week HIIT program safe for people with prior SCAD, assessed by the occurrence of MACE?
Researchers will compare two randomized groups (1:1):
- Group A (HIIT): Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks, with continuous heart rate monitoring and clear rules for stopping in case of symptoms.
- Group B (usual care): Participants continue with the exercise advice they have already received after SCAD, without a structured supervised program and with a recommendation to avoid high-intensity exercise (above 85% of maximum heart rate).
Participants in both groups will:
- Undergo cardiopulmonary exercise testing (CPET) at baseline and after 12 weeks to measure VO2peak and blood pressure response during exercise.
- Have blood tests (for example cholesterol and cardiac biomarkers), blood pressure, heart rate and weight measured.
- Complete validated questionnaires on quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), and depression (Patient Health Questionnaire-9 (PHQ-9)).
- Have activity data recorded using the MIA activity-tracking app and heart rate data will be uploaded simultaneously from portable devices.
Safety will be monitored continuously. Major adverse cardiovascular events (MACE), including death, recurrent heart attack (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary arterial dissection, cardioversion or implantable cardioverter-defibrillator (ICD) therapy, will be recorded during the 12-week intervention and a 25-week follow-up period (total study duration per participant: 37 weeks).
Read the detailed description
Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic cause of acute coronary syndrome that predominantly affects younger, otherwise healthy women. It is characterized by a dissection and/or intramural hematoma in the coronary artery wall, leading to impaired coronary blood flow and myocardial infarction. SCAD typically occurs in women around the perimenopausal period, but a substantial proportion of patients are even younger, and SCAD is a leading cause of pregnancy-associated myocardial infarction. Traditional cardiovascular risk factors are often absent, whereas conditions such as fibromuscular dysplasia and migraine are more common. Emotional stress, and to a lesser extent physical stress, is frequently reported around the time of the event. This profile makes SCAD a distinctly sex-related cardiovascular disease: female-dominated, closely linked to hormonal transitions, non-atherosclerotic, and often preceded by severe psychosocial stress.
In contrast to other forms of coronary disease, evidence-based guidance on exercise and cardiac rehabilitation after SCAD is lacking. Most recommendations are extrapolated from atherosclerotic coronary disease and do not reflect the different risk profile and rehabilitation needs of SCAD survivors. Many patients are advised to avoid high-intensity exercise based on precaution rather than data, and structured rehabilitation is frequently omitted. Observational data suggest that fewer than half of SCAD patients meet general physical activity recommendations, and preliminary findings from the Norwegian Spontaneous Coronary Artery Dissection study (NOR-SCAD) indicate that many have lost physical fitness and do not reach age-expected peak oxygen uptake (VO2peak, ml/kg/min). Restrictive advice may therefore contribute to inactivity, loss of fitness, weight gain, persistent symptoms, and psychological distress, including fear of exertion and anxiety about recurrence. Importantly, there are no robust data demonstrating that usual physical activity increases the risk of recurrent SCAD. This combination of a predominantly female, younger patient group, a strong need for rehabilitation, and limited evidence on exercise safety creates a major gap in sex-specific cardiovascular care.
The Norwegian Spontaneous Coronary Artery Dissection Exercise trial (NOR-SCAD-Ex) is a randomized controlled trial conducted in Norway to address this evidence gap. Adult women and men aged ≥18 years with prior, confirmed SCAD at least 12 weeks before enrollment, who are medically stable and cleared for cardiopulmonary exercise testing (CPET) and supervised exercise, are eligible. After baseline assessments, participants are randomized 1:1 to either a 12-week supervised, treadmill-based high-intensity interval training (HIIT) program or usual care with an upper intensity restriction. All participants receive guideline-directed medical therapy and standard clinical follow-up independent of group allocation. CPET is performed at baseline and at 12 weeks using standardized procedures for calibration, performance, and quality control. VO2peak is defined as the highest 30-second average of oxygen uptake (ml/kg/min) during CPET. In addition to CPET, participants undergo blood pressure and heart rate measurements, routine blood tests (including lipids and cardiac biomarkers), and complete validated patient-reported outcome measures: quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), depression (Patient Health Questionnaire-9 (PHQ-9)) and relevant symptom questionnaires.
The HIIT intervention consists of supervised sessions delivered by trained physiotherapists, typically using treadmill walking or running with individualized speed and incline. Each session includes a warm-up period at low-to-moderate intensity, followed by repeated 4-minute high-intensity intervals targeting approximately 85-95% of peak heart rate or Borg scale ratings of 15-18, interspersed with active recovery periods at about 60-70% of peak heart rate (Borg 11-13). Heart rate is monitored continuously using portable devices to document training intensity and adherence. Participants and physiotherapists are instructed to stop exercise immediately if chest pain, dizziness, palpitations or other symptoms suggestive of cardiovascular intolerance occur, and prespecified rules guide modification or termination of sessions.
Participants allocated to usual care do not receive a structured supervised exercise program during the 12-week intervention period. They are advised to continue their usual physical activity patterns but to avoid high-intensity exercise, defined as sustained effort above 85% of maximum heart rate. To characterize real-world exercise behavior in the control group, participants are provided with heart rate monitors and simple training diaries to record type, duration, and perceived intensity of physical activity. This allows detailed comparison of physical activity patterns between groups and assessment of potential contamination (high-intensity training) in the usual care arm.
Safety is a central focus of the study. Eligibility criteria include exclusion of conditions with strict exercise restrictions (such as major heritable aortic diseases), exercise-induced severe hypertension (e.g. systolic blood pressure > 220 mmHg) or complex ventricular arrhythmias during baseline CPET (e.g. non-sustained ventricular tachycardia >3 beats), and current pregnancy. Safety is monitored throughout the 12-week intervention and an additional 25-week follow-up period (total study duration per participant: 37 weeks). Major adverse cardiovascular events (MACE) including death, recurrent myocardial infarction (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary artery dissection, cardioversion, and implantable cardioverter-defibrillator therapy, as well as serious adverse events and clinically significant arrhythmias, are systematically recorded and adjudicated. A Data Monitoring Committee (DMC) regularly reviews unblinded safety data and applies predefined stopping rules, including a Bayesian-based safety stopping rule, to ensure that the trial can be modified or terminated if unacceptable risk emerges.
Beyond the primary focus on VO2peak and MACE, the trial incorporates exploratory evaluation of blood pressure responses to exercise, including hypertensive response to exercise (HRE), and their potential sex-specific implications. HRE, quantified using systolic blood pressure relative to workload, may unmask latent hypertension and has been associated with future cardiovascular events independent of resting blood pressure. Because SCAD is a female-dominated, non-atherosclerotic coronary disease with reported overlaps with pregnancy complications and other vascular disorders, HRE may help identify subgroups with increased vascular risk who could benefit from targeted follow-up. The study also uses digital tools (such as the MIA activity-tracking app and portable heart rate monitors) to characterize physical activity patterns and heart rate responses in everyday life, providing additional insight into how SCAD survivors engage in exercise under different recommendations.
The overarching hypothesis is that a carefully supervised HIIT program will produce clinically meaningful improvements in cardiorespiratory fitness (a between-group difference in VO2peak of at least 2.5 ml/kg/min) compared with usual care, without an unacceptable increase in MACE. Secondary and exploratory hypotheses include that HIIT will improve quality of life and reduce symptoms of anxiety and depression, that supervised exercise training will favorably modify HRE and other cardiovascular risk markers, and that structured rehabilitation can reduce fear of exertion and support a safe return to physical activity in this vulnerable, predominantly female patient population. By integrating objective measures of fitness, blood pressure, and activity with patient-reported outcomes and rigorous safety monitoring, NOR-SCAD-Ex aims to provide the first randomized evidence on the efficacy and safety of HIIT after SCAD in Norway and to inform future, SCAD-specific exercise and rehabilitation recommendations.
- Conditions
- Spontaneous Coronary Artery Dissection, Myocardial Infarction (MI), High Intensity Interval Training
- Being tested
- High intensity interval training (HIIT)
- Keywords
- SCAD, Exercise, HIIT, MACE, Spontaneous coronary artery dissection, High intensity interval training
- Medical subject headings
- Coronary Artery Dissection, Spontaneous, Myocardial Infarction, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High intensity interval training (HIIT)Other
Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks. Each session is 4 minutes x 4 at target heart rate between 85-95% of maximum HR.
| Study group | Role | What they receive |
|---|---|---|
| Group A - High intensity interval training (HIIT) | Experimental | Intervention Receives: Other: High intensity interval training (HIIT) |
| Group B - Usual Care | No intervention | Usual care with exercise restriction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline to 12 weeks in peak oxygen uptake (VO2peak, ml/kg/min) measured by CPET
Measured: From enrollment to the end of intervention (12 weeks)
Secondary outcomes (9)
MACE (composite of recurrent SCAD, TIA/stroke, extra-coronary artery dissection,death and/or aborted cardiac arrest)
Safety endpoint. Incidence of MACE (composite of recurrent SCAD, TIA/stroke, extra-coronary artery dissection,death and/or aborted cardiac arrest).
Measured: From enrollment to end of follow-up period (12 weeks + 25 weeks)
Incidence of MACE (recurrent SCAD alone)
Safety endpoint. Incidence of MACE (recurrent SCAD alone)
Measured: From enrollment to end of follow-up period (12 weeks + 25 weeks)
Incidence of MACE (death or aborted cardiac arrest)
Safety endpoint. Incidence of MACE (death or aborted cardiac arrest)
Measured: From enrollment to end of follow-up period (12 weeks + 25 weeks)
Change in quality of life
Quality of Life assessed by validated questionnaire: World Health Organization Quality of Life-BREF (WHOQOL-BREF)
Measured: From enrollment to end of intervention (12 weeks)
Change in depression
Change in depression assessed by validated questionnaire: Patient Health Questionnaire-9 (PHQ-9)
Measured: From enrollment to end of intervention (12 weeks)
Change in anxiety
Change in anxiety measured by validated questionnaire: Generalized Anxiety Disorder 7-item scale (GAD-7)
Measured: From enrollment to end of intervention (12 weeks)
Changes in blood pressure at rest and hypertensive response to exercise (HRE)
HRE will be measured during cardio-pulmonary-exercise test (CPET) before and after study intervention (12 weeks) in both HIIT-group and usual care-group. The trial will use HRE relative to fitness (SBT/METs) and will be tested at predefined points (low, moderat and high intensity) during a modified Balke protocol.
Measured: From enrollment to end of study intervention (12 weeks)
Changes in weight
weight (kg) measured before and after intervention
Measured: From enrollment to end of study intervention (12 weeks)
Change in lipid profile
Change in lipid profile (Total cholesterol, LDL, HDL) in mmol/L
Measured: From enrollment to end of study intervention (12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start1 Jan 2027 (estimated)
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Spontaneous Coronary Artery DissectionStudies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Clinical Trial Unit (CTU), Oslo University Hospital, University of Oslo
- Responsible party
- Principal investigator, Kristina Hermann Haugaa, Oslo University Hospital
- Investigators
- Kristina Hermann Haugaa, Phd, Principal investigator, Rikshospitalet, Oslo Univeristy Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07785765
- Sponsor's protocol ID
- REKnr 975719
- Acronym
- NorDen-SCAD Ex
- Status last verified
- Aug 2026
- First submitted
- 14 Aug 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plan to share individual participant data (IPD). Due to ethical and privacy considerations and limitations in the current consent and data governance framework, only aggregate (summary) results will be shared through publications and posting on ClinicalTrials.gov.
Publications
Hilton SE, Thiessen JS, Rycroft AD, Miners NI, Bommarito JC, Matharu TS, Khangura PK, Stapleton RK, Rocha LC, Nardone M, Millar PJ. Influence of sex and aerobic fitness on blood pressure during maximal treadmill exercise in young healthy adults. J Appl Physiol (1985). 2025 Jun 1;138(6):1321-1326. doi: 10.1152/japplphysiol.00056.2025. Epub 2025 May 5.
PubMed 40323584Schultz MG, Otahal P, Roberts-Thomson P, Stanton T, Hamilton-Craig C, Wahi S, La Gerche A, Hare JL, Selvanayagam J, Maiorana A, Venn AJ, Marwick TH, Sharman JE. Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. Eur Heart J. 2026 Apr 7;47(14):1661-1671. doi: 10.1093/eurheartj/ehaf1082.
PubMed 41528824De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, Cauldwell M, Cerbai E, Crotti L, de Groot NMS, Estensen ME, Goossens ES, Haring B, Kurpas D, McEniery CM, Peters SAE, Rakisheva A, Sambola A, Schlager O, Schoenhoff FS, Simoncini T, Steinbach F, Sudano I, Swan L, Valente AM; ESC Scientific Document Group. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025 Nov 14;46(43):4462-4568. doi: 10.1093/eurheartj/ehaf193. No abstract available.
PubMed 40878294Heath A, Offringa M, Pechlivanoglou P, Rios JD, Klassen TP, Poonai N, Pullenayegum E; KidsCAN PERC Innovative Paediatric Clinical Trials Team. Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes. Contemp Clin Trials Commun. 2020 Apr 8;18:100561. doi: 10.1016/j.conctc.2020.100561. eCollection 2020 Jun.
PubMed 32300671Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2022 Sep 13;80(11):1091-1106. doi: 10.1016/j.jacc.2022.07.004.
PubMed 36075680Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43. doi: 10.1016/j.jacc.2003.07.028.
PubMed 14680741Stensvold D, Viken H, Steinshamn SL, Dalen H, Stoylen A, Loennechen JP, Reitlo LS, Zisko N, Baekkerud FH, Tari AR, Sandbakk SB, Carlsen T, Ingebrigtsen JE, Lydersen S, Mattsson E, Anderssen SA, Fiatarone Singh MA, Coombes JS, Skogvoll E, Vatten LJ, Helbostad JL, Rognmo O, Wisloff U. Effect of exercise training for five years on all cause mortality in older adults-the Generation 100 study: randomised controlled trial. BMJ. 2020 Oct 7;371:m3485. doi: 10.1136/bmj.m3485.
PubMed 33028588Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, Beckers P, Bobenko A, Hommel J, Van de Heyning CM, Esefeld K, von Korn P, Christle JW, Haykowsky MJ, Linke A, Wisloff U, Adams V, Pieske B, van Craenenbroeck EM, Halle M; OptimEx-Clin Study Group. Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2021 Feb 9;325(6):542-551. doi: 10.1001/jama.2020.26812.
PubMed 33560320Battenberg AE, Carey P, Larson KF, Hayes SN, Smith JR, Baker SE, Bonikowske AR, Tweet MS. Spontaneous Coronary Artery Dissection in Highly Active Individuals: Insights From a Prospective Registry. JACC Adv. 2026 Feb;5(2):102485. doi: 10.1016/j.jacadv.2025.102485. Epub 2026 Jan 2.
PubMed 41483544Chacin-Suarez AS, Bonikowske AR, Medina-Inojosa JR, Gulati R, Best PJ, Hayes SN, Tweet MS. Physical Activity and Exercise Patterns After Spontaneous Coronary Artery Dissection: Insights From a Large Multinational Registry. Front Cardiovasc Med. 2021 Jun 15;8:642739. doi: 10.3389/fcvm.2021.642739. eCollection 2021.
PubMed 34212011Kim SK, Wing-Lun E, Chandrasekhar J, Puri A, Burgess S, Ford TJ, Kovacic J, Graham RM, Psaltis PJ, Zaman S. The Australian New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry - A Multi-Centre Cohort Study: Protocol, Background and Significance. Heart Lung Circ. 2022 Dec;31(12):1612-1618. doi: 10.1016/j.hlc.2022.08.018. Epub 2022 Sep 28.
PubMed 36180304Saw J, Starovoytov A, Aymong E, Inohara T, Alfadhel M, McAlister C, Samuel R, Grewal T, Parolis JA, Sheth T, So D, Minhas K, Brass N, Lavoie A, Bishop H, Lavi S, Pearce C, Renner S, Madan M, Welsh RC, McGrath BM, Vijayaraghavan R, Har B, Ibrahim R, Chaudhary P, Ganesh SK, Graham J, Matteau A, Martucci G, Ko DT, Humphries K, Mancini GJ. Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes. J Am Coll Cardiol. 2022 Oct 25;80(17):1585-1597. doi: 10.1016/j.jacc.2022.08.759.
PubMed 36265953
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Norwegian Danish Spontaneous Coronary Artery Dissection Exercise Study
- ClinicalTrials.gov ID
- NCT07785765
- Acronym / sponsor ID
- NorDen-SCAD Ex / REKnr 975719
- Conditions
- Spontaneous Coronary Artery Dissection, Myocardial Infarction (MI), High Intensity Interval Training
- Keywords
- SCAD, Exercise, HIIT, MACE, Spontaneous coronary artery dissection, High intensity interval training
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Oslo University HospitalUniversity, hospital or other
- Collaborators
- Clinical Trial Unit (CTU), Oslo University Hospital, University of Oslo
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized clinical trial is to determine whether a supervised high-intensity interval training (HIIT) program can safely improve cardiorespiratory fitness and overall health in adults who have previously had spontaneous coronary artery dissection (SCAD), a non-atherosclerotic cause of heart attack that often affects younger women.
Participants are women and men aged 18 years or older, with a confirmed SCAD at least 12 weeks before enrollment, who are medically stable, cleared for exercise testing, and able to attend supervised sessions.
The main questions the study aims to answer are:
- Does a 12-week supervised HIIT program lead to a greater improvement in cardiorespiratory fitness (measured as peak oxygen uptake (VO2peak, ml/kg/min)) compared with usual care, without increasing the occurrence of major adverse cardiovascular events (MACE)?
- Is a 12-week HIIT program safe for people with prior SCAD, assessed by the occurrence of MACE?
Researchers will compare two randomized groups (1:1):
- Group A (HIIT): Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks, with continuous heart rate monitoring and clear rules for stopping in case of symptoms.
- Group B (usual care): Participants continue with the exercise advice they have already received after SCAD, without a structured supervised program and with a recommendation to avoid high-intensity exercise (above 85% of maximum heart rate).
Participants in both groups will:
- Undergo cardiopulmonary exercise testing (CPET) at baseline and after 12 weeks to measure VO2peak and blood pressure response during exercise.
- Have blood tests (for example cholesterol and cardiac biomarkers), blood pressure, heart rate and weight measured.
- Complete validated questionnaires on quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), and depression (Patient Health Questionnaire-9 (PHQ-9)).
- Have activity data recorded using the MIA activity-tracking app and heart rate data will be uploaded simultaneously from portable devices.
Safety will be monitored continuously. Major adverse cardiovascular events (MACE), including death, recurrent heart attack (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary arterial dissection, cardioversion or implantable cardioverter-defibrillator (ICD) therapy, will be recorded during the 12-week intervention and a 25-week follow-up period (total study duration per participant: 37 weeks).
Detailed description
Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic cause of acute coronary syndrome that predominantly affects younger, otherwise healthy women. It is characterized by a dissection and/or intramural hematoma in the coronary artery wall, leading to impaired coronary blood flow and myocardial infarction. SCAD typically occurs in women around the perimenopausal period, but a substantial proportion of patients are even younger, and SCAD is a leading cause of pregnancy-associated myocardial infarction. Traditional cardiovascular risk factors are often absent, whereas conditions such as fibromuscular dysplasia and migraine are more common. Emotional stress, and to a lesser extent physical stress, is frequently reported around the time of the event. This profile makes SCAD a distinctly sex-related cardiovascular disease: female-dominated, closely linked to hormonal transitions, non-atherosclerotic, and often preceded by severe psychosocial stress.
In contrast to other forms of coronary disease, evidence-based guidance on exercise and cardiac rehabilitation after SCAD is lacking. Most recommendations are extrapolated from atherosclerotic coronary disease and do not reflect the different risk profile and rehabilitation needs of SCAD survivors. Many patients are advised to avoid high-intensity exercise based on precaution rather than data, and structured rehabilitation is frequently omitted. Observational data suggest that fewer than half of SCAD patients meet general physical activity recommendations, and preliminary findings from the Norwegian Spontaneous Coronary Artery Dissection study (NOR-SCAD) indicate that many have lost physical fitness and do not reach age-expected peak oxygen uptake (VO2peak, ml/kg/min). Restrictive advice may therefore contribute to inactivity, loss of fitness, weight gain, persistent symptoms, and psychological distress, including fear of exertion and anxiety about recurrence. Importantly, there are no robust data demonstrating that usual physical activity increases the risk of recurrent SCAD. This combination of a predominantly female, younger patient group, a strong need for rehabilitation, and limited evidence on exercise safety creates a major gap in sex-specific cardiovascular care.
The Norwegian Spontaneous Coronary Artery Dissection Exercise trial (NOR-SCAD-Ex) is a randomized controlled trial conducted in Norway to address this evidence gap. Adult women and men aged ≥18 years with prior, confirmed SCAD at least 12 weeks before enrollment, who are medically stable and cleared for cardiopulmonary exercise testing (CPET) and supervised exercise, are eligible. After baseline assessments, participants are randomized 1:1 to either a 12-week supervised, treadmill-based high-intensity interval training (HIIT) program or usual care with an upper intensity restriction. All participants receive guideline-directed medical therapy and standard clinical follow-up independent of group allocation. CPET is performed at baseline and at 12 weeks using standardized procedures for calibration, performance, and quality control. VO2peak is defined as the highest 30-second average of oxygen uptake (ml/kg/min) during CPET. In addition to CPET, participants undergo blood pressure and heart rate measurements, routine blood tests (including lipids and cardiac biomarkers), and complete validated patient-reported outcome measures: quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), depression (Patient Health Questionnaire-9 (PHQ-9)) and relevant symptom questionnaires.
The HIIT intervention consists of supervised sessions delivered by trained physiotherapists, typically using treadmill walking or running with individualized speed and incline. Each session includes a warm-up period at low-to-moderate intensity, followed by repeated 4-minute high-intensity intervals targeting approximately 85-95% of peak heart rate or Borg scale ratings of 15-18, interspersed with active recovery periods at about 60-70% of peak heart rate (Borg 11-13). Heart rate is monitored continuously using portable devices to document training intensity and adherence. Participants and physiotherapists are instructed to stop exercise immediately if chest pain, dizziness, palpitations or other symptoms suggestive of cardiovascular intolerance occur, and prespecified rules guide modification or termination of sessions.
Participants allocated to usual care do not receive a structured supervised exercise program during the 12-week intervention period. They are advised to continue their usual physical activity patterns but to avoid high-intensity exercise, defined as sustained effort above 85% of maximum heart rate. To characterize real-world exercise behavior in the control group, participants are provided with heart rate monitors and simple training diaries to record type, duration, and perceived intensity of physical activity. This allows detailed comparison of physical activity patterns between groups and assessment of potential contamination (high-intensity training) in the usual care arm.
Safety is a central focus of the study. Eligibility criteria include exclusion of conditions with strict exercise restrictions (such as major heritable aortic diseases), exercise-induced severe hypertension (e.g. systolic blood pressure > 220 mmHg) or complex ventricular arrhythmias during baseline CPET (e.g. non-sustained ventricular tachycardia >3 beats), and current pregnancy. Safety is monitored throughout the 12-week intervention and an additional 25-week follow-up period (total study duration per participant: 37 weeks). Major adverse cardiovascular events (MACE) including death, recurrent myocardial infarction (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary artery dissection, cardioversion, and implantable cardioverter-defibrillator therapy, as well as serious adverse events and clinically significant arrhythmias, are systematically recorded and adjudicated. A Data Monitoring Committee (DMC) regularly reviews unblinded safety data and applies predefined stopping rules, including a Bayesian-based safety stopping rule, to ensure that the trial can be modified or terminated if unacceptable risk emerges.
Beyond the primary focus on VO2peak and MACE, the trial incorporates exploratory evaluation of blood pressure responses to exercise, including hypertensive response to exercise (HRE), and their potential sex-specific implications. HRE, quantified using systolic blood pressure relative to workload, may unmask latent hypertension and has been associated with future cardiovascular events independent of resting blood pressure. Because SCAD is a female-dominated, non-atherosclerotic coronary disease with reported overlaps with pregnancy complications and other vascular disorders, HRE may help identify subgroups with increased vascular risk who could benefit from targeted follow-up. The study also uses digital tools (such as the MIA activity-tracking app and portable heart rate monitors) to characterize physical activity patterns and heart rate responses in everyday life, providing additional insight into how SCAD survivors engage in exercise under different recommendations.
The overarching hypothesis is that a carefully supervised HIIT program will produce clinically meaningful improvements in cardiorespiratory fitness (a between-group difference in VO2peak of at least 2.5 ml/kg/min) compared with usual care, without an unacceptable increase in MACE. Secondary and exploratory hypotheses include that HIIT will improve quality of life and reduce symptoms of anxiety and depression, that supervised exercise training will favorably modify HRE and other cardiovascular risk markers, and that structured rehabilitation can reduce fear of exertion and support a safe return to physical activity in this vulnerable, predominantly female patient population. By integrating objective measures of fitness, blood pressure, and activity with patient-reported outcomes and rigorous safety monitoring, NOR-SCAD-Ex aims to provide the first randomized evidence on the efficacy and safety of HIIT after SCAD in Norway and to inform future, SCAD-specific exercise and rehabilitation recommendations.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A - High intensity interval training (HIIT) | Experimental | Other: High intensity interval training (HIIT)Intervention |
| Group B - Usual Care | No intervention | –Usual care with exercise restriction |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Confirmed SCAD, at least 12 weeks since last event, age 18 years or older, medically stable and cleared for CPET and supervised exercise
Key exclusion criteria (1 listed)
- Disease with exercise restrictions, exercise related severe hypertension on CPET (>220 mmHg in Systolic blood pressure or >110mmHg in Diastolic blood pressure)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High intensity interval training (HIIT)Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks. Each session is 4 minutes x 4 at target heart rate between 85-95% of maximum HR. | Other | Group A - High intensity interval training (HIIT) |
Primary outcome
Change from baseline to 12 weeks in peak oxygen uptake (VO2peak, ml/kg/min) measured by CPET
Time frame: From enrollment to the end of intervention (12 weeks)
9 secondary outcomes
MACE (composite of recurrent SCAD, TIA/stroke, extra-coronary artery dissection,death and/or aborted cardiac arrest)
Time frame: From enrollment to end of follow-up period (12 weeks + 25 weeks)
Incidence of MACE (recurrent SCAD alone)
Time frame: From enrollment to end of follow-up period (12 weeks + 25 weeks)
Incidence of MACE (death or aborted cardiac arrest)
Time frame: From enrollment to end of follow-up period (12 weeks + 25 weeks)
Change in quality of life
Time frame: From enrollment to end of intervention (12 weeks)
Change in depression
Time frame: From enrollment to end of intervention (12 weeks)
Change in anxiety
Time frame: From enrollment to end of intervention (12 weeks)
Changes in blood pressure at rest and hypertensive response to exercise (HRE)
Time frame: From enrollment to end of study intervention (12 weeks)
Changes in weight
Time frame: From enrollment to end of study intervention (12 weeks)
Change in lipid profile
Time frame: From enrollment to end of study intervention (12 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Background: PubMed 40323584Hilton SE, Thiessen JS, Rycroft AD, Miners NI, Bommarito JC, Matharu TS, Khangura PK, Stapleton RK, Rocha LC, Nardone M, Millar PJ. Influence of sex and aerobic fitness on blood pressure during maximal treadmill exercise in young healthy adults. J Appl Physiol (1985). 2025 Jun 1;138(6):1321-1326. doi: 10.1152/japplphysiol.00056.2025. Epub 2025 May 5.
- Background: PubMed 41528824Schultz MG, Otahal P, Roberts-Thomson P, Stanton T, Hamilton-Craig C, Wahi S, La Gerche A, Hare JL, Selvanayagam J, Maiorana A, Venn AJ, Marwick TH, Sharman JE. Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. Eur Heart J. 2026 Apr 7;47(14):1661-1671. doi: 10.1093/eurheartj/ehaf1082.
- Background: PubMed 40878294De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, Cauldwell M, Cerbai E, Crotti L, de Groot NMS, Estensen ME, Goossens ES, Haring B, Kurpas D, McEniery CM, Peters SAE, Rakisheva A, Sambola A, Schlager O, Schoenhoff FS, Simoncini T, Steinbach F, Sudano I, Swan L, Valente AM; ESC Scientific Document Group. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025 Nov 14;46(43):4462-4568. doi: 10.1093/eurheartj/ehaf193. No abstract available.
- Background: PubMed 32300671Heath A, Offringa M, Pechlivanoglou P, Rios JD, Klassen TP, Poonai N, Pullenayegum E; KidsCAN PERC Innovative Paediatric Clinical Trials Team. Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes. Contemp Clin Trials Commun. 2020 Apr 8;18:100561. doi: 10.1016/j.conctc.2020.100561. eCollection 2020 Jun.
- Background: PubMed 36075680Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2022 Sep 13;80(11):1091-1106. doi: 10.1016/j.jacc.2022.07.004.
- Background: PubMed 14680741Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43. doi: 10.1016/j.jacc.2003.07.028.
- Background: PubMed 33028588Stensvold D, Viken H, Steinshamn SL, Dalen H, Stoylen A, Loennechen JP, Reitlo LS, Zisko N, Baekkerud FH, Tari AR, Sandbakk SB, Carlsen T, Ingebrigtsen JE, Lydersen S, Mattsson E, Anderssen SA, Fiatarone Singh MA, Coombes JS, Skogvoll E, Vatten LJ, Helbostad JL, Rognmo O, Wisloff U. Effect of exercise training for five years on all cause mortality in older adults-the Generation 100 study: randomised controlled trial. BMJ. 2020 Oct 7;371:m3485. doi: 10.1136/bmj.m3485.
- Background: PubMed 33560320Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, Beckers P, Bobenko A, Hommel J, Van de Heyning CM, Esefeld K, von Korn P, Christle JW, Haykowsky MJ, Linke A, Wisloff U, Adams V, Pieske B, van Craenenbroeck EM, Halle M; OptimEx-Clin Study Group. Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2021 Feb 9;325(6):542-551. doi: 10.1001/jama.2020.26812.
- Background: PubMed 41483544Battenberg AE, Carey P, Larson KF, Hayes SN, Smith JR, Baker SE, Bonikowske AR, Tweet MS. Spontaneous Coronary Artery Dissection in Highly Active Individuals: Insights From a Prospective Registry. JACC Adv. 2026 Feb;5(2):102485. doi: 10.1016/j.jacadv.2025.102485. Epub 2026 Jan 2.
- Background: PubMed 34212011Chacin-Suarez AS, Bonikowske AR, Medina-Inojosa JR, Gulati R, Best PJ, Hayes SN, Tweet MS. Physical Activity and Exercise Patterns After Spontaneous Coronary Artery Dissection: Insights From a Large Multinational Registry. Front Cardiovasc Med. 2021 Jun 15;8:642739. doi: 10.3389/fcvm.2021.642739. eCollection 2021.
- Background: PubMed 36180304Kim SK, Wing-Lun E, Chandrasekhar J, Puri A, Burgess S, Ford TJ, Kovacic J, Graham RM, Psaltis PJ, Zaman S. The Australian New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry - A Multi-Centre Cohort Study: Protocol, Background and Significance. Heart Lung Circ. 2022 Dec;31(12):1612-1618. doi: 10.1016/j.hlc.2022.08.018. Epub 2022 Sep 28.
- Background: PubMed 36265953Saw J, Starovoytov A, Aymong E, Inohara T, Alfadhel M, McAlister C, Samuel R, Grewal T, Parolis JA, Sheth T, So D, Minhas K, Brass N, Lavoie A, Bishop H, Lavi S, Pearce C, Renner S, Madan M, Welsh RC, McGrath BM, Vijayaraghavan R, Har B, Ibrahim R, Chaudhary P, Ganesh SK, Graham J, Matteau A, Martucci G, Ko DT, Humphries K, Mancini GJ. Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes. J Am Coll Cardiol. 2022 Oct 25;80(17):1585-1597. doi: 10.1016/j.jacc.2022.08.759.
- Individual participant dataSharing planned: No. No plan to share individual participant data (IPD). Due to ethical and privacy considerations and limitations in the current consent and data governance framework, only aggregate (summary) results will be shared through publications and posting on ClinicalTrials.gov.
Related trials for Spontaneous Coronary Artery Dissection
Recruiting
A Study Of Exercise In Patients With Spontaneous Coronary Artery Dissection And Fibromuscular Dysplasia
Fibromuscular Dysplasia, Spontaneous Coronary Artery Dissection
Not yet recruitingPhase 4
Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial
SCAD, ACS (Acute Coronary Syndrome)
Enrolling by invitationObservational study
Spontaneous Coronary Artery Dissection (SCAD) Avatar Study
Spontaneous Coronary Artery Dissection
RecruitingObservational study
Defining the Basis of Fibromuscular Dysplasia (FMD)
Fibromuscular Dysplasia, Spontaneous Coronary Artery Dissection
Recruiting
A Study to Analyze the Role of Sympathetic Nervous System in Spontaneous Coronary Artery Dissection
Spontaneous Coronary Artery Dissection, Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kristina Hermann Haugaa, Phd principal investigator
Rikshospitalet, Oslo Univeristy Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High intensity interval training (HIIT) in people with Spontaneous Coronary Artery Dissection and Myocardial Infarction (MI), run by Oslo University Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline to 12 weeks in peak oxygen uptake (VO2peak, ml/kg/min) measured by CPET (time frame: From enrollment to the end of intervention (12 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07785765, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.